摘要
目的探讨达格列净对早期糖尿病肾病患者的治疗效果及对尿酸和肌酐水平的影响。方法选取2020年1月—2021年9月在该院接受治疗的早期糖尿病肾病患者50例,根据随机数表法分为两组,对照组25例患者实施二甲双胍治疗,观察组25例患者实施达格列净治疗。检测两组患者空腹血糖、糖化血红蛋白、血肌酐、血尿酸、尿微量白蛋白/尿肌酐比值水平,同时观察两组患者用药后的不良反应(低血糖、呕吐、感染)发生情况,比较临床治疗总有效率。结果观察组患者FPG(5.63±1.02)mmol/L、HbA1c(5.01±1.24)%、SCr(60.23±12.34)μmol/L、SUA(301.61±33.45)μmol/L、UMA/UCr(87.91±25.32)mg/g水平均优于对照组的(7.07±3.12)mmol/L、(7.28±1.08)%、(71.14±17.94)μmol/L、(332.20±43.29)μmol/L、(117.63±28.54)mg/g,差异有统计学意义(P<0.05);观察组患者低血糖、呕吐和感染不良反应发生率12.00%(3/25)与对照组24.00%(6/25)比较,差异无统计学意义(P>0.05);观察组患者治疗总有效率为96.00%(24/25),较对照组72.00%(18/25)明显更高,差异有统计学意义(P<0.05)。结论达格列净治疗早期糖尿病肾病患者的效果显著,可改善患者尿酸和肌酐等指标状况,减少患者用药不良反应的发生率,是理想的治疗药物,值得临床重视并推广应用。
Objective To investigate the therapeutic effect of dapagliflozin on patients with early diabetic nephropathy and its influence on uric acid and creatinine levels.Methods 50 patients with early diabetic nephropathy who received treatment in the hospital from January 2020 to September 2021 were selected.According to the random number table method,they were divided into two groups.25 patients in the control group were treated with metformin and 25 patients in the observation group were treated with dapagliflozin.Detected the fasting blood glucose,glycosylated hemoglobin,blood creatinine,blood uric acid and urinary microalbumin/urinary creatinine ratio of the two groups.At the same time,the occurrence of adverse reactions(hypoglycemia,vomiting and infection)after medication was observed,and the total effectiveness of clinical treatment was compared.Results The levels of FPG(5.63±1.02)mmol/L,HbA1c(5.01±1.24)%,SCr(60.23±12.34)μmol/L,SUA(301.61±33.45)μmol/L,UMA/Ucr(87.91±25.32)mg/g in the observation group were significantly better than those in the control group(7.07±3.12)mmol/L,(7.28±1.08)%,(71.14±17.94)μmol/L,(332.20±43.29)μmol/L,and(117.63±28.54)mg/g,the difference was statistically significant(P<0.05).The incidence of hypoglycemia,vomiting and infection in the observation group was 12.00%(3/25),compared with 24.00%(6/25)in the control group,the difference was not statistically significant(P>0.05).The total effective rate of the observation group was 96.00%(24/25),which was significantly higher than that of the control group 72.00%(18/25),and the difference was statistically significant(P<0.05).Conclusion Dagglitazone is effective in the treatment of patients with early diabetes nephropathy.It can improve the status of uric acid,creatinine and other indicators,and reduce the incidence of adverse drug reactions in patients.It is an ideal therapeutic drug and is worthy of clinical attention and promotion.
作者
范梦榕
倪小燕
FAN Mengrong;NI Xiaoyan(Department of Nephrology,Rugao Bo'ai Hospital,Nantong,Jiangsu Province,226500 China)
出处
《糖尿病新世界》
2022年第11期187-190,共4页
Diabetes New World Magazine
关键词
达格列净
早期糖尿病肾病
尿酸
肌酐
不良反应
治疗总有效率
Dapagliflozin
Early diabetic nephropathy
Uric acid
Creatinine
Adverse reactions
Total effective rate
